251. Prognostic Value of Serum Galectin-3 in Chronic Heart Failure: A Meta-Analysis.
- Author
-
Cheng Z, Cai K, Xu C, Zhan Q, Xu X, Xu D, and Zeng Q
- Abstract
Objective: To evaluate the association between serum galectin-3 and all-cause death (ACD) and cardiovascular death (CVD) in patients with chronic heart failure (CHF)., Methods: The PubMed and Embase databases and Clinical Trials Registry (www.clinicaltrials.gov) were searched for studies with data on serum galectin-3 and ACD and CVD in CHF patients. The hazard ratios (HRs) of ACD and CVD were calculated and presented with 95% CIs. HRs were pooled using fixed effects or random effects models when appropriate. Sensitivity analysis, meta-regression and subgroup analysis were applied to find the origin of heterogeneity. Visual inspection of Begg's funnel plot and Egger's test were performed to assess the possibility publication bias., Results: Pooled data included the results from 6,440 patients from 12 studies in the meta-analysis. Higher serum galectin-3 was associated with a higher risk of ACD (HR, 1.38; 95% CI, 1.14-1.67) and CVD (HR, 1.13; 95% CI, 1.02-1.25) in CHF patients. In the subgroup analyses, higher serum galectin-3 was associated with an increased risk of ACD in all subgroups. The pooled HR of the shorter follow-up group (1.78; 95% CI, 1.50-2.11) was significantly higher than the pooled HR of the longer follow-up group (1.15; 95% CI, 1.05-1.25). Sensitivity analysis of eliminating one study in each turn indicated that Koukoui et al.'s study had the largest influence on the risk of all-cause death. All-cause death publication bias was not detected (Pr>|z| = 0.35 for Begg's test and P>|t| = 0.15 for Egger's test)., Conclusions: Serum galectin-3 has prognostic value of both all-cause death and cardiovascular death in CHF. Serum galectin-3 could be useful for risk classification in patients with CHF., Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=193399., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Cheng, Cai, Xu, Zhan, Xu, Xu and Zeng.)
- Published
- 2022
- Full Text
- View/download PDF